Erratum: Enhancer of zeste homolog 2 inhibition attenuates renal fibrosis by maintaining Smad7 and ohosphatase and tensin homolog expression (Journal of the American Society of Nephrology (2016) 27 (2092-2108) DOI: 10.1681/ASN.2015040457);Enhancer of zeste homolog 2 inhibition attenuates renal fibrosis by maintaining Smad7 and phosphatase and tensin homolog expression

Journal of the American Society of Nephrology

Volumn 27, Issue 7, 2016, Pages 2092-2108

  Zhou, Xiaoxu ^a,b   Zang, Xiujuan ^a,c   Ponnusamy, Murugavel ^a   Masucci, Monica V ^a   Tolbert, Evelyn ^a   Gong, Rujun ^a   Zhao, Ting C ^d   Liu, Na ^e   Bayliss, George ^a   Dworkin, Lance D ^a   Zhuang, Shougang ^a,e  

^a BROWN UNIVERSITY   (United States)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c Shanghai Songjiang District Central Hospital   (China)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 DEAZANEPLANOCIN A; ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; EPIDERMAL GROWTH FACTOR RECEPTOR; GSK 126; HISTONE H3; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN INHIBITOR; SMAD3 PROTEIN; SMAD7 PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR EZH2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA1; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; PTEN PROTEIN, MOUSE; SMAD7 PROTEIN, MOUSE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; FIBROBLAST; FOCAL GLOMERULOSCLEROSIS; G2 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; HISTONE METHYLATION; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN A NEPHROPATHY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FIBROSIS; KIDNEY TUBULE CELL; MALE; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; RENAL PROTECTION; TGF BETA SIGNALING; URETER OBSTRUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; FIBROSIS; KIDNEY; KIDNEY DISEASES; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; FIBROBLASTS; FIBROSIS; KIDNEY; KIDNEY DISEASES; MALE; MICE; PTEN PHOSPHOHYDROLASE; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 85006047198     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2017040437     Document Type: Erratum

References (75)

1. Liu Y: Epithelial to mesenchymal transition in renal fibrogenesis: Pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 15: 1–12, 2004
2. Neilson EG: Mechanisms of disease: Fibroblasts–a new look at an old problem. Nat Clin Pract Nephrol 2: 101–108, 2006
3. Wynn TA: Cellular and molecular mechanisms of fibrosis. J Pathol 214: 199–210, 2008
4. Meran S, Steadman R: Fibroblasts and myofibroblasts in renal fibrosis. Int J Exp Pathol 92: 158–167, 2011
5. Bonner JC: Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 15: 255–273, 2004
6. Terzi F, Burtin M, Hekmati M, Federici P, Grimber G, Briand P, Friedlander G: Targeted expression of a dominant-negative EGF-R in the kidney reduces tubulo-interstitial lesions after renal injury. J Clin Invest 106: 225–234, 2000
7. Lautrette A, Li S, Alili R, Sunnarborg SW, Burtin M, Lee DC, Friedlander G, Terzi F: Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: A new therapeutic approach. Nat Med 11: 867–874, 2005
8. Wang W, Koka V, Lan HY: Transforming growth factor-beta and Smad signalling in kidney diseases. Nephrology (Carlton) 10: 48–56, 2005
9. Qin H, Wang L, Feng T, Elson CO, Niyongere SA, Lee SJ, Reynolds SL, Weaver CT, Roarty K, Serra R, Benveniste EN, Cong Y: TGF-beta promotes Th17 cell development through inhibition of SOCS3. J Immunol 183: 97–105, 2009
10. Song CY, Kim BC, Hong HK, Lee HS: TGF-beta type II receptor deficiency prevents renal injury via decrease in ERK activity in crescentic glo-merulonephritis. Kidney Int 71: 882–888, 2007
11. Suzuki K, Wilkes MC, Garamszegi N, Edens M, Leof EB: Transforming growth factor beta signaling via Ras in mesenchymal cells requires p21-activated kinase 2 for extracellular signal-regulated kinase-dependent transcriptional responses. Cancer Res 67: 3673–3682, 2007
12. Vignais ML, Sadowski HB, Watling D, Rogers NC, Gilman M: Platelet-derived growth factor induces phosphorylation of multiple JAK family kinases and STAT proteins. Mol Cell Biol 16: 1759–1769, 1996
13. Lo HW, Hsu SC, Xia W, Cao X, Shih JY, Wei Y, Abbruzzese JL, Hortobagyi GN, Hung MC: Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res 67: 9066–9076, 2007
14. Trojanowska M: Noncanonical transforming growth factor beta signaling in scleroderma fibrosis. Curr Opin Rheumatol 21: 623–629, 2009
15. Tampe B, Zeisberg M: Evidence for the involvement of epigenetics in the progression of renal fibrogenesis. Nephrol Dial Transplant 29[Suppl 1]: i1–i8, 2014
16. Wing MR, Ramezani A, Gill HS, Devaney JM, Raj DS: Epigenetics of progression of chronic kidney disease: Fact or fantasy? Semin Nephrol 33: 363–374, 2013
17. Hassler MR, Egger G: Epigenomics of cancer - emerging new concepts. Biochimie 94: 2219–2230, 2012
18. Ledford H: Epigenetics: Marked for success. Nature 483: 637–639, 2012
19. Maher ER: Genomics and epigenomics of renal cell carcinoma. Semin Cancer Biol 23: 10–17, 2013
20. Sandoval J, Esteller M: Cancer epigenomics: Beyond genomics. Curr Opin Genet Dev 22: 50–55, 2012
21. Pang M, Kothapally J, Mao H, Tolbert E, Ponnusamy M, Chin YE, Zhuang S: Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol 297: F996–F1005, 2009
22. Bechtel W, McGoohan S, Zeisberg EM, Müller GA, Kalbacher H, Salant DJ, Müller CA, Kalluri R, Zeisberg M: Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med 16: 544–550, 2010
23. Cao R, Zhang Y: The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev 14: 155–164, 2004
24. Morey L, Helin K: Polycomb group protein-mediated repression of transcription. Trends Biochem Sci 35: 323–332, 2010
25. Margueron R, Reinberg D: The Polycomb complex PRC2 and its mark in life. Nature 469: 343–349, 2011
26. Shen H, Laird PW: Interplay between the cancer genome and epige-nome. Cell 153: 38–55, 2013
27. Wagener N, Macher-Goeppinger S, Pritsch M, Hüsing J, Hoppe-Seyler K, Schirmacher P, Pfitzenmaier J, Haferkamp A, Hoppe-Seyler F, Hohenfellner M: Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer 10: 524, 2010
28. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624–629, 2002
29. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA, Chinnaiyan AM: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 100: 11606–11611, 2003
30. Yu J, Yu J, Rhodes DR, Tomlins SA, Cao X, Chen G, Mehra R, Wang X, Ghosh D, Shah RB, Varambally S, Pienta KJ, Chinnaiyan AM: A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 67: 10657–10663, 2007
31. Gonzalez ME, Li X, Toy K, DuPrie M, Ventura AC, Banerjee M, Ljungman M, Merajver SD, Kleer CG: Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene 28: 843–853, 2009
32. Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, Ravoori MK, Shahzad MM, Lee JW, Mora E, Langley RR, Carroll AR, Matsuo K, Spannuth WA, Schmandt R, Jennings NB, Goodman BW, Jaffe RB, Nick AM, Kim HS, Guven EO, Chen YH, Li LY, Hsu MC, Coleman RL, Calin GA, Denkbas EB, Lim JY, Lee JS, Kundra V, Birrer MJ, Hung MC, Lopez-Berestein G, Sood AK: Regulation of tumor angiogenesis by EZH2. Cancer Cell 18: 185–197, 2010
33. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RK, Tan PB, Liu ET, Yu Q: Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 21: 1050–1063, 2007
34. Hibino S, Saito Y, Muramatsu T, Otani A, Kasai Y, Kimura M, Saito H: Inhibitors of enhancer of zeste homolog 2 (EZH2) activate tumor-suppressor microRNAs in human cancer cells. Oncogenesis 3: e104, 2014
35. Mack M, Yanagita M: Origin of myofibroblasts and cellular events triggering fibrosis. Kidney Int 87: 297–307, 2015
36. Duffield JS: Cellular and molecular mechanisms in kidney fibrosis. J Clin Invest 124: 2299–2306, 2014
37. Loeffler I, Wolf G: Transforming growth factor-b and the progression of renal disease. Nephrol Dial Transplant 29[Suppl 1]: i37–i45, 2014
38. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra A 3rd, Diaz E, LaFrance LV, Mellinger M, Duquenne C, Tian X, Kruger RG, McHugh CF, Brandt M, Miller WH, Dhanak D, Verma SK, Tummino PJ, Creasy CL: EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492: 108–112, 2012
39. Liu Y: Renal fibrosis: New insights into the pathogenesis and therapeutics. Kidney Int 69: 213–217, 2006
40. Schnaper HW, Jandeska S, Runyan CE, Hubchak SC, Basu RK, Curley JF, Smith RD, Hayashida T: TGF-beta signal transduction in chronic kidney disease. Front Biosci (Landmark Ed) 14: 2448–2465, 2009
41. Abbate M, Zoja C, Rottoli D, Corna D, Tomasoni S, Remuzzi G: Proximal tubular cells promote fibrogenesis by TGF-beta1-mediated induction of peritubular myofibroblasts. Kidney Int 61: 2066–2077, 2002
42. Coimbra TM, Carvalho J, Fattori A, Da Silva CG, Lachat JJ: Transforming growth factor-beta production during the development of renal fibrosis in rats with subtotal renal ablation. Int J Exp Pathol 77: 167–173, 1996
43. Ludewig D, Kosmehl H, Sommer M, Böhmer FD, Stein G: PDGF receptor kinase blocker AG1295 attenuates interstitial fibrosis in rat kidney after unilateral obstruction. Cell Tissue Res 299: 97–103, 2000
44. Benoit YD, Witherspoon MS, Laursen KB, Guezguez A, Beauséjour M, Beaulieu JF, Lipkin SM, Gudas LJ: Pharmacological inhibition of polycomb repressive complex-2 activity induces apoptosis in human colon cancer stem cells. Exp Cell Res 319: 1463–1470, 2013
45. Abouantoun TJ, Castellino RC, MacDonald TJ: Sunitinib induces PTEN expression and inhibits PDGFR signaling and migration of medulloblastoma cells. J Neurooncol 101: 215–226, 2011
46. Rosivatz E, Matthews JG, McDonald NQ, Mulet X, Ho KK, Lossi N, Schmid AC, Mirabelli M, Pomeranz KM, Erneux C, Lam EW, Vilar R, Woscholski R: A small molecule inhibitor for phosphatase and tensin homologue deleted on chromosome 10 (PTEN). ACS Chem Biol 1: 780–790, 2006
47. Han Y, Masaki T, Hurst LA, Ikezumi Y, Trzaskos JM, Atkins RC, Nikolic-Paterson DJ: Extracellular signal-regulated kinase-dependent interstitial macrophage proliferation in the obstructed mouse kidney. Nephrology (Carlton) 13: 411–418, 2008
48. Yang L, Besschetnova TY, Brooks CR, Shah JV, Bonventre JV: Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med 16: 535–543, 2010
49. Bonventre JV: Primary proximal tubule injury leads to epithelial cell cycle arrest, fibrosis, vascular rarefaction, and glomerulosclerosis. Kidney Int Suppl (2011) 4: 39–44, 2014
50. Atta H, El-Rehany M, Hammam O, Abdel-Ghany H, Ramzy M, Roderfeld M, Roeb E, Al-Hendy A, Raheim SA, Allam H, Marey H: Mutant MMP-9 and HGF gene transfer enhance resolution of CCl4-induced liver fibrosis in rats: Role of ASH1 and EZH2 methyltransferases repression. PLoS One 9: e112384, 2014
51. Coward WR, Feghali-Bostwick CA, Jenkins G, Knox AJ, Pang L: A central role for G9a and EZH2 in the epigenetic silencing of cyclooxygenase-2 in idiopathic pulmonary fibrosis. FASEB J 28: 3183–3196, 2014
52. Hobert O, Sures I, Ciossek T, Fuchs M, Ullrich A: Isolation and developmental expression analysis of Enx-1, a novel mouse Polycomb group gene. Mech Dev 55: 171–184, 1996
53. Margueron R, Li G, Sarma K, Blais A, Zavadil J, Woodcock CL, Dynlacht BD, Reinberg D: Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol Cell 32: 503–518, 2008
54. Deb G, Singh AK, Gupta S: EZH2: Not EZHY (easy) to deal. Mol Cancer Res 12: 639–653, 2014
55. Böttinger EP: TGF-beta in renal injury and disease. Semin Nephrol 27: 309–320, 2007
56. Lan HY, Chung AC: TGF-b/Smad signaling in kidney disease. Semin Nephrol 32: 236–243, 2012
57. Tian Y, Liao F, Wu G, Chang D, Yang Y, Dong X, Zhang Z, Zhang Y, Wu G: Ubiquitination and regulation of Smad7 in the TGF-b1/Smad signaling of aristolochic acid nephropathy. Toxicol Mech Methods 25: 645–652, 2015
58. Mann J, Chu DC, Maxwell A, Oakley F, Zhu NL, Tsukamoto H, Mann DA: MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology 138: 705–714, 2010
59. Hazra S, Xiong S, Wang J, Rippe RA, Krishna V, Chatterjee K, Tsukamoto H: Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells. J Biol Chem 279: 11392–11401, 2004
60. Miyahara T, Schrum L, Rippe R, Xiong S, Yee HF Jr., Motomura K, Anania FA, Willson TM, Tsukamoto H: Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 275: 35715–35722, 2000
61. Kawai T, Masaki T, Doi S, Arakawa T, Yokoyama Y, Doi T, Kohno N, Yorioka N: PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. Lab Invest 89: 47–58, 2009
62. Wang W, Liu F, Chen N: Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists attenuate the profibrotic response induced by TGF-beta1 in renal interstitial fibroblasts. Mediators In-flamm 2007: 62641, 2007
63. Liu N, Tolbert E, Pang M, Ponnusamy M, Yan H, Zhuang S: Suramin inhibits renal fibrosis in chronic kidney disease. J Am Soc Nephrol 22: 1064–1075, 2011
64. Pang M, Ma L, Gong R, Tolbert E, Mao H, Ponnusamy M, Chin YE, Yan H, Dworkin LD, Zhuang S: A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy. Kidney Int 78: 257–268, 2010
65. Kim E, Kim M, Woo DH, Shin Y, Shin J, Chang N, Oh YT, Kim H, Rheey J, Nakano I, Lee C, Joo KM, Rich JN, Nam DH, Lee J: Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell 23: 839–852, 2013
66. Krämer OH, Heinzel T: Phosphorylation-acetylation switch in the regulation of STAT1 signaling. Mol Cell Endocrinol 315: 40–48, 2010
67. Alimova I, Venkataraman S, Harris P, Marquez VE, Northcott PA, Dubuc A, Taylor MD, Foreman NK, Vibhakar R: Targeting the enhancer of zeste homologue 2 in medulloblastoma. Int J Cancer 131: 1800–1809, 2012
68. Kemp CD, Rao M, Xi S, Inchauste S, Mani H, Fetsch P, Filie A, Zhang M, Hong JA, Walker RL, Zhu YJ, Ripley RT, Mathur A, Liu F, Yang M, Meltzer PA, Marquez VE, De Rienzo A, Bueno R, Schrump DS: Polycomb repressor complex-2 is a novel target for mesothelioma therapy. Clin Cancer Res 18: 77–90, 2012
69. Kalushkova A, Fryknäs M, Lemaire M, Fristedt C, Agarwal P, Eriksson M, Deleu S, Atadja P, Osterborg A, Nilsson K, Vanderkerken K, Oberg F, Jernberg-Wiklund H: Polycomb target genes are silenced in multiple myeloma. PLoS One 5: e11483, 2010
70. Gannon OM, Merida de Long L, Endo-Munoz L, Hazar-Rethinam M, Saunders NA: Dysregulation of the repressive H3K27 trimethylation mark in head and neck squamous cell carcinoma contributes to dysregulated squamous differentiation. Clin Cancer Res 19: 428–441, 2013
71. Qi W, Chan H, Teng L, Li L, Chuai S, Zhang R, Zeng J, Li M, Fan H, Lin Y, Gu J, Ardayfio O, Zhang JH, Yan X, Fang J, Mi Y, Zhang M, Zhou T, Feng G, Chen Z, Li G, Yang T, Zhao K, Liu X, Yu Z, Lu CX, Atadja P, Li E: Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A 109: 21360–21365, 2012
72. Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR, Sacks JD, Raimondi A, Majer CR, Song J, Scott MP, Jin L, Smith JJ, Olhava EJ, Chesworth R, Moyer MP, Richon VM, Copeland RA, Keilhack H, Pollock RM, Kuntz KW: A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 8: 890–896, 2012
73. Knutson SK, Kawano S, Minoshima Y, Warholic NM, Huang KC, Xiao Y, Kadowaki T, Uesugi M, Kuznetsov G, Kumar N, Wigle TJ, Klaus CR, Allain CJ, Raimondi A, Waters NJ, Smith JJ, Porter-Scott M, Chesworth R, Moyer MP, Copeland RA, Richon VM, Uenaka T, Pollock RM, Kuntz KW, Yokoi A, Keilhack H: Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther 13: 842–854, 2014
74. Sun F, Lee L, Zhang Z, Wang X, Yu Q, Duan X, Chan E: Preclinical pharmacokinetic studies of 3-deazaneplanocin A, a potent epigenetic anticancer agent, and its human pharmacokinetic prediction using GastroPlus. Eur J Pharm Sci 77: 290–302, 2015
75. Krämer M, Dees C, Huang J, Schlottmann I, Palumbo-Zerr K, Zerr P, Gelse K, Beyer C, Distler A, Marquez VE, Distler O, Schett G, Distler JH: Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis. Ann Rheum Dis 72: 614–620, 2013